| Brand name (active ingredient) | Disease Area | Approved and marketed | Owner |
| Chenodeoxycholic acid Leadiant (chenodeoxycholic acid) | Cerebrotendinous Xanthomatosis | Approved in the EU | Leadiant Biosciences Ltd. |
| Natulan (procarbazine) | *Hodgkin lymphoma and brain cancers | *Approved in the EU | Leadiant Biosciences Ltd. |
Updated June 2017
*List not exhaustive.
Important Note
For patients: if you wish to report an adverse event related to one of our products, please contact your healthcare provider. In addition, you can contact us on safety@leadiantbiosciences.com.
For healthcare professionals: if you wish to report an adverse event related to one of our products, please follow the current regulatory procedure in force in your country or contact us at safety@leadiantbiosciences.com.
If your residence is in the U.S. or Canada, please consult the North American website for details on safety reporting.
